Clinical trials
Hepatocellular Carcinoma clinical trials
Below are recruiting hepatocellular carcinoma clinical trials, each written for real people, not researchers. We’re tracking 581 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05062837RecruitingPhase 2/Phase 3
Surgery plus two drugs for advanced liver cancer
This trial combines surgery to remove liver tumors with two drugs, camrelizumab (an immunotherapy that helps your immune system fight cancer) and apatinib (a targeted therapy that may cut off the tumor's blood supply). It aims to see if this combination helps people with advanced liver cancer that has spread outside the liver (but not to the brain) and who have chosen not to have other standard treatments like TACE or radiation. Participating could potentially control the spreading cancer and improve outcomes.
NanningAges 18–75 - NCT07617038Enrolling by invitation
MRI Scan to Predict Liver Cancer Treatment Response
This trial uses a special type of MRI scan to see if doctors can predict how well a liver cancer treatment (called TACE) will work for you. The scan may help doctors understand your treatment response better.
Montreal, QuebecAges 18–70 - NCT07500220RecruitingPhase 1/Phase 2
Dual-target CAR-NK cell therapy for advanced liver cancer
This trial tests a new cell therapy made from natural killer (NK) cells that are engineered to attack two targets (GPC3 and B7-H3) found on liver cancer cells. It may be an option for people with advanced liver cancer who have already tried standard treatments.
Shenzhen, GuangdongAges 18–75 - NCT07495215RecruitingPhase 1/Phase 2
Personalized mRNA vaccine plus immunotherapy for liver cancer after surgery
This trial tests a personalized mRNA vaccine (iNeo-Vac-R01) combined with a PD-1 inhibitor to prevent liver cancer from coming back after surgery. It is for people with early-stage liver cancer who have a high risk of recurrence.
Hangzhou, ZhejiangAges 18–75 - NCT07430202RecruitingPhase 1
Vaccine plus drug combination for advanced fibrolamellar carcinoma
This study tests a new vaccine (a shot that may help your immune system attack cancer cells) combined with a glutamine-blocking drug (DRP-104) and two immunotherapy drugs (nivolumab and ipilimumab) for advanced fibrolamellar carcinoma. It aims to see if this combination can shrink tumors or slow their growth.
Baltimore, MarylandAges 12 years+
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hepatocellular carcinoma?
- Yes. Clin2 currently lists 581 recruiting hepatocellular carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hepatocellular carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hepatocellular carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.